Purchase this article with an account.
J.J. Fromow–Guerra, A. Solis–Vivanco, E. Reyna–Castelan, J. Jimenez–Sierra, J. Guerrero–Naranjo, G. Alvarez, M. Martinez, V. Morales–Canton, H. Quiroz–Mercado; The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3852.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the clinical outcome of patients receiving an intravitreal (I–V) injection of the monoclonal antibody Bevacizumab as treatment of diabetic macular edema (DME)
A non–randomized prospective clinical interventional study which include 45 non previously treated patients with DME. The patients received a single I–V injection of (0.1 cc) bevacizumab. Follow–up included clinical examination (best corrected LogMAR visual acuity (VA), intraocular pressure (IOP), catarat grading, DME characteristics and systemic check–up) pre–injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT, fluorescein angiography and multifocal electroretinogram (MFE) was evaluated at months 1 and 3
There were no vision or life threatening adverse events. No significant IOP increases neither lens opacities were recorded. Mean VA improved from 20/80 to 20/40 from the 2 week and remain stable until the 3 month follow–up (Friedman Test p= 0.001). Retinal thickness diminished from 347±195 µ to 259±127.3µ at the 1st month and remain stable (Wilcoxon Test p=0.009). Macular leakage area diminished since the 1st month from 9.17±3.8 DD to 6.12 ± 3.44 DD (Wilcoxon Test p= 0.007).
A single injection of Bevacizumab seamed to be effective in the treatment of DME at 3 month follow–up, without adverse events. A comparative randomized study is needed.
This PDF is available to Subscribers Only